BREASTESTplus 2 clinically validated
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The test is set for commercial launch in November, starting in major Australian cities before a national rollout. This non-invasive test aims to provide additional information to women and their healthcare providers, enhancing breast health assessments. BCAL is advancing its accreditation and commercialization efforts in preparation for the launch.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
BCAL Diagnostics Limited on 6ix
Earlier from BCAL Diagnostics
- BCAL Introduces Avantect Multi-Cancer Early Detection Test
- Appendix 4E and Annual Report to shareholders
- BCAL Takes Interest in Genetic Signatures to 18.46%
- BCAL Secures Funding for FY2027 Update
- BCAL to Acquire Shares in Genetic Signatures
Later from BCAL Diagnostics
- GSS: Response to Media Speculation & BCAL letter to GSS
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics